Earnings Summary

Theravance Biopharma Inc’s revenue fell -83.23% since last year same period to $3.09Mn in the Q1 2017. On a quarterly growth basis, Theravance Biopharma Inc has generated -45.77% fall in its revenue since last 3-months.

Theravance Biopharma Inc’s net profit fell -54.97% since last year same period to $-65.32Mn in the Q1 2017. On a quarterly growth basis, Theravance Biopharma Inc has generated 2.99% jump in its net profits since last 3-months.

Theravance Biopharma Inc’s net profit margin fell -824.19% since last year same period to -2115.94% in the Q1 2017. On a quarterly growth basis, Theravance Biopharma Inc has generated -78.87% fall in its net profit margins since last 3-months.

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.09 - a 50% jump from last quarter’s estimates.

Theravance Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.09.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Theravance Biopharma Inc’s return on assets (ROA) stands at -0.1.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Theravance Biopharma Inc’s return on equity (ROE) stands at -1.8.